The development of bioactive small molecules as probes or drug candidates requires
discovery platforms that enable access to chemical diversity and can quickly reveal new …

Living systems use proximity to regulate biochemical processes. Inspired by this
phenomenon, bifunctional modalities that induce proximity have been developed to redirect …

Proteolysis targeting chimeras (PROTACs) are bifunctional compounds that recruit an E3
ligase to a target protein to induce ubiquitination and degradation of the target. Rational …

Targeted protein degradation and stabilization are promising therapeutic modalities
because of their potency, versatility and their potential to expand the druggable target …

In recent years, with the successful development of proteolysis-targeting chimeric molecules
(PROTACs), the potential of heterobifunctional molecules to contribute to reenvisioning drug …

Targeted protein degradation (TPD) has emerged as a potentially transformational
therapeutic modality with considerable promise. Molecular glue degraders remodel the …

Simple Summary The small ubiquitin-like modifier (SUMO) pathway regulates the hallmark
properties of cancer cells. Moreover, alterations in activity and in levels of SUMO machinery …

Challenging disease targets necessitate new approaches for therapeutic intervention.
Rewiring protein-biomolecule interactions with proximity-inducing agents extends …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

1BB as a co-stimulatory receptor represents a next-generation therapeutic target in immune-
oncology, which has been targeted by agonist antibodies or embedded in CAR-T cell …